. . . . . . . . . . . . . . . . . . . . . . . . . "1110072375"^^ . . . "Formas frontera de la esclerosis m\u00FAltiple"@es . . . . . . . . . . . . . . . . . . . . . . "Se conoce como formas frontera de la esclerosis m\u00FAltiple al conjunto de enfermedades que no se pueden clasificar a ciencia cierta como dentro o fuera del espectro de la esclerosis m\u00FAltiple. Son las siguientes: \n* Encefalomielitis aguda diseminada \n* Esclerosis conc\u00E9ntrica de Balo \n* \n* \n* \n* Neuromielitis \u00F3ptica \n* Datos: Q5988897"@es . . "Source does not mention anti-TNF therapy"@en . . . . . . "It relies too heavily on primary sources"@en . . . . . . . . . . . . . . . . . . . . "July 2022"@en . . . . . . . . . . . . . . . "\u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0627\u0644\u062A\u0647\u0627\u0628\u064A\u0629 \u0627\u0644\u0645\u064F\u0632\u064A\u0644\u0629 \u0644\u0644\u0645\u064A\u0627\u0644\u064A\u0646\u060C \u0648\u062A\u0633\u0645\u0649 \u0623\u062D\u064A\u0627\u0646\u064B\u0627 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0627\u0644\u062A\u0647\u0627\u0628\u064A\u0629 \u0627\u0644\u0645\u064F\u0632\u064A\u0644\u0629 \u0644\u0644\u0645\u064A\u0627\u0644\u064A\u0646 \u0645\u062C\u0647\u0648\u0644\u0629 \u0627\u0644\u0633\u0628\u0628 \u0628\u0633\u0628\u0628 \u0628\u0642\u0627\u0621 \u0628\u0639\u0636 \u0627\u0644\u0645\u0633\u0628\u0628\u0627\u062A \u0645\u062C\u0647\u0648\u0644\u0629 \u0644\u063A\u0627\u064A\u0629 \u0627\u0644\u0622\u0646\u060C \u0648\u064A\u0639\u0631\u0651\u0641\u0647\u0627 \u0627\u0644\u0628\u0639\u0636 \u0623\u062D\u064A\u0627\u0646\u064B\u0627 \u0643\u0623\u0634\u0643\u0627\u0644 \u062D\u062F\u0648\u062F\u064A\u0629 \u0644\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0623\u0648 \u0643\u0623\u0645\u0631\u0627\u0636 \u0645\u062E\u062A\u0644\u0641\u0629\u060C \u0648\u0644\u0643\u0646 \u064A\u0639\u062A\u0628\u0631\u0647\u0627 \u0622\u062E\u0631\u0648\u0646 \u0637\u064A\u0641\u064B\u0627 \u0645\u0646 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u064A\u062E\u062A\u0644\u0641 \u0641\u0642\u0637 \u0645\u0646 \u062D\u064A\u062B \u0627\u0644\u0625\u0632\u0645\u0627\u0646 \u0648\u0627\u0644\u0634\u062F\u0629 \u0648\u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064A\u0631\u064A. \u064A\u062E\u0636\u0639 \u0647\u0630\u0627 \u0627\u0644\u0645\u0648\u0636\u0648\u0639 \u0644\u0628\u062D\u062B \u0645\u0643\u062B\u0641 \u0648\u0645\u0646 \u0627\u0644\u0645\u062A\u0648\u0642\u0639 \u0623\u0646 \u062A\u0646\u0645\u0648 \u0642\u0627\u0626\u0645\u0629 \u0627\u0644\u0623\u062C\u0633\u0627\u0645 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0627\u0644\u0630\u0627\u062A\u064A\u0629 \u0644\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0641\u064A \u0627\u0644\u0645\u0633\u062A\u0642\u0628\u0644 \u0627\u0644\u0642\u0631\u064A\u0628."@ar . . . . . . . . . . . . "100752"^^ . . . . . . . . . . . . . . . "\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u062A\u0647\u0627\u0628\u064A\u0629 \u0645\u0632\u064A\u0644\u0629 \u0644\u0644\u0645\u064A\u0627\u0644\u064A\u0646 \u0641\u064A \u0627\u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0639\u0635\u0628\u064A \u0627\u0644\u0645\u0631\u0643\u0632\u064A"@ar . . "Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course."@en . . "8576311"^^ . "\u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0627\u0644\u062A\u0647\u0627\u0628\u064A\u0629 \u0627\u0644\u0645\u064F\u0632\u064A\u0644\u0629 \u0644\u0644\u0645\u064A\u0627\u0644\u064A\u0646\u060C \u0648\u062A\u0633\u0645\u0649 \u0623\u062D\u064A\u0627\u0646\u064B\u0627 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0627\u0644\u062A\u0647\u0627\u0628\u064A\u0629 \u0627\u0644\u0645\u064F\u0632\u064A\u0644\u0629 \u0644\u0644\u0645\u064A\u0627\u0644\u064A\u0646 \u0645\u062C\u0647\u0648\u0644\u0629 \u0627\u0644\u0633\u0628\u0628 \u0628\u0633\u0628\u0628 \u0628\u0642\u0627\u0621 \u0628\u0639\u0636 \u0627\u0644\u0645\u0633\u0628\u0628\u0627\u062A \u0645\u062C\u0647\u0648\u0644\u0629 \u0644\u063A\u0627\u064A\u0629 \u0627\u0644\u0622\u0646\u060C \u0648\u064A\u0639\u0631\u0651\u0641\u0647\u0627 \u0627\u0644\u0628\u0639\u0636 \u0623\u062D\u064A\u0627\u0646\u064B\u0627 \u0643\u0623\u0634\u0643\u0627\u0644 \u062D\u062F\u0648\u062F\u064A\u0629 \u0644\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0623\u0648 \u0643\u0623\u0645\u0631\u0627\u0636 \u0645\u062E\u062A\u0644\u0641\u0629\u060C \u0648\u0644\u0643\u0646 \u064A\u0639\u062A\u0628\u0631\u0647\u0627 \u0622\u062E\u0631\u0648\u0646 \u0637\u064A\u0641\u064B\u0627 \u0645\u0646 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u064A\u062E\u062A\u0644\u0641 \u0641\u0642\u0637 \u0645\u0646 \u062D\u064A\u062B \u0627\u0644\u0625\u0632\u0645\u0627\u0646 \u0648\u0627\u0644\u0634\u062F\u0629 \u0648\u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064A\u0631\u064A. \u064A\u0639\u062A\u0628\u0631 \u0627\u0644\u0628\u0639\u0636 \u0627\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0645\u062A\u0644\u0627\u0632\u0645\u0629 \u0648\u0644\u064A\u0633 \u0645\u0631\u0636 \u0648\u062D\u064A\u062F. \u062D\u062A\u0649 \u0639\u0627\u0645 2019\u060C \u0639\u064F\u062B\u0650\u0631 \u0639\u0644\u0649 \u062B\u0644\u0627\u062B\u0629 \u0623\u062C\u0633\u0627\u0645 \u0645\u0636\u0627\u062F\u0629 \u0630\u0627\u062A\u064A\u0629 \u0641\u064A \u0645\u0631\u0636 \u0627\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0639\u0635\u0628\u064A \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u063A\u064A\u0631 \u0627\u0644\u0646\u0645\u0637\u064A \u0627\u0644\u0630\u064A \u064A\u0636\u0645 \u0623\u0645\u0631\u0627\u0636\u064B\u0627 \u0645\u0646\u0641\u0635\u0644\u0629: \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0644\u0623\u0643\u0648\u0627\u0628\u0648\u0631\u064A\u0646 4 \u0648\u0623\u0637\u064A\u0627\u0641 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u062F\u0628\u0642\u064A\u0629 \u0642\u0644\u064A\u0644\u0629 \u0627\u0644\u062A\u063A\u0635\u0646 \u0627\u0644\u0645\u064A\u0627\u0644\u064A\u0646\u064A \u0627\u0644\u0633\u0643\u0631\u064A \u0648\u0627\u0644\u0646\u064A\u0648\u0631\u0648\u0641\u0627\u0633\u064A\u0646. \u0633\u064F\u062C\u0650\u0651\u0644\u062A \u0623\u064A\u0636\u064B\u0627 \u062D\u0627\u0644\u0627\u062A \u0645\u0646 \u0627\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0639\u0635\u0628\u064A \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0627\u0644\u0645\u0631\u062A\u0628\u0637\u0629 \u0628\u0627\u0639\u062A\u0644\u0627\u0644 \u0644\u064A\u0628\u0631 \u0627\u0644\u0639\u0635\u0628\u064A \u0627\u0644\u0628\u0635\u0631\u064A \u0627\u0644\u0648\u0631\u0627\u062B\u064A\u060C \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0637\u064A\u0641 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u0631\u062A\u0628\u0637\u0629 \u0628\u0639\u0627\u0645\u0644 \u0627\u0644\u0646\u062E\u0631 \u0627\u0644\u0648\u0631\u0645\u064A \u0627\u0644\u0645\u0633\u062A\u062D\u062B\u0629 \u0628\u0627\u0644\u0623\u062F\u0648\u064A\u0629 (\u0648\u0627\u0644\u062A\u064A \u0644\u0627 \u064A\u0645\u0643\u0646 \u062A\u0645\u064A\u064A\u0632\u0647\u0627 \u0639\u0646 \u0627\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0627\u0644\u0639\u0627\u062F\u064A \u0628\u0645\u0639\u0631\u0641\u062A\u0646\u0627 \u0627\u0644\u062D\u0627\u0644\u064A\u0629). \u064A\u062E\u0636\u0639 \u0647\u0630\u0627 \u0627\u0644\u0645\u0648\u0636\u0648\u0639 \u0644\u0628\u062D\u062B \u0645\u0643\u062B\u0641 \u0648\u0645\u0646 \u0627\u0644\u0645\u062A\u0648\u0642\u0639 \u0623\u0646 \u062A\u0646\u0645\u0648 \u0642\u0627\u0626\u0645\u0629 \u0627\u0644\u0623\u062C\u0633\u0627\u0645 \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0627\u0644\u0630\u0627\u062A\u064A\u0629 \u0644\u0644\u062A\u0635\u0644\u0628 \u0627\u0644\u0645\u062A\u0639\u062F\u062F \u0641\u064A \u0627\u0644\u0645\u0633\u062A\u0642\u0628\u0644 \u0627\u0644\u0642\u0631\u064A\u0628."@ar . . . . . . . . . . . . . "Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course. Multiple sclerosis for some people is a syndrome more than a single disease. As of 2019, three auto-antibodies have been found in atypical MS giving birth to separate diseases: Anti-AQP4 diseases, Anti-MOG and Anti-NF spectrums. A LHON-associated MS has also been reported, and in addition there have been inconclusive reports of TNF-\u03B1 blockers inducing demyelinating disorders. The subject is under intense research and the list of MS autoantibodies is expected to grow in the near future."@en . . . . . "Inflammatory demyelinating diseases of the central nervous system"@en . . . . . "Se conoce como formas frontera de la esclerosis m\u00FAltiple al conjunto de enfermedades que no se pueden clasificar a ciencia cierta como dentro o fuera del espectro de la esclerosis m\u00FAltiple. Son las siguientes: \n* Encefalomielitis aguda diseminada \n* Esclerosis conc\u00E9ntrica de Balo \n* \n* \n* \n* Neuromielitis \u00F3ptica \n* Datos: Q5988897"@es . . . "the lesions only \"appear to be consistent with demyelination\" + primary source"@en . . . . . . . . . . . . . . . "June 2022"@en . . .